NO975620L - Immunologiske kombinasjonssammensetninger og fremgangsmåter - Google Patents
Immunologiske kombinasjonssammensetninger og fremgangsmåterInfo
- Publication number
- NO975620L NO975620L NO975620A NO975620A NO975620L NO 975620 L NO975620 L NO 975620L NO 975620 A NO975620 A NO 975620A NO 975620 A NO975620 A NO 975620A NO 975620 L NO975620 L NO 975620L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- lipoprotein
- compositions
- antigen
- combination compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Immunologiske sammensetninger og fremgangsmåter ved deres anvendelse. Sammensetningene inneholder minst ett antigen og minst ett lipoprotein, og valgfritt et hjel- pestoff. Lipoproteinet kan i og for seg være antigent eller immunogent. Antigenet kan være influensa-HA, og lipoproteinet kan være et rekombinant uttrykt produkt som har en OspA-leder for lipidering, og PspA for pro- teinandelen. Antigenet kan være OspC, og lipoproteinet kan være OspA. Komponentene av sammensetningen admi- nistreres sammen. En styrket immunologisk respons opp- nås med sammensetningene og metodene.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/476,656 US6251405B1 (en) | 1995-06-07 | 1995-06-07 | Immunological combination compositions and methods |
US08/588,621 US6379675B1 (en) | 1995-06-07 | 1996-01-19 | Immunological combination compositions and methods |
PCT/US1996/008866 WO1996040290A1 (en) | 1995-06-07 | 1996-06-05 | Immunological combination compositions and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
NO975620D0 NO975620D0 (no) | 1997-12-04 |
NO975620L true NO975620L (no) | 1998-02-04 |
Family
ID=23892726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO975620A NO975620L (no) | 1995-06-07 | 1997-12-04 | Immunologiske kombinasjonssammensetninger og fremgangsmåter |
Country Status (12)
Country | Link |
---|---|
US (5) | US6251405B1 (no) |
EP (1) | EP0831937B1 (no) |
JP (1) | JPH11510370A (no) |
AT (1) | ATE249844T1 (no) |
AU (1) | AU717890B2 (no) |
CA (1) | CA2223041A1 (no) |
DE (1) | DE69630033T2 (no) |
FI (1) | FI118591B (no) |
IL (1) | IL118579A (no) |
NO (1) | NO975620L (no) |
WO (1) | WO1996040290A1 (no) |
ZA (1) | ZA964894B (no) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
ZA964896B (en) * | 1995-06-07 | 1997-01-08 | Connaught Lab | Expression of lipoproteins |
WO1998051283A1 (en) * | 1997-05-14 | 1998-11-19 | Galen (Chemicals) Limited | Topical compositions |
CA2304128A1 (en) * | 1997-09-18 | 1999-03-25 | Robert Becker | Improved method of production of pneumococcal surface proteins |
EP1087788A1 (fr) * | 1998-06-26 | 2001-04-04 | Aventis Pasteur | Immunisation a ciblage mucosal |
PT1126876E (pt) * | 1998-10-16 | 2007-04-30 | Glaxosmithkline Biolog Sa | Sistemas adjuvantes e vacinas |
CA2358385C (en) | 1998-12-31 | 2013-08-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
AT407958B (de) | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
AU764969B2 (en) | 1999-04-19 | 2003-09-04 | Smithkline Beecham Biologicals (Sa) | Vaccines |
US7060281B1 (en) | 1999-06-18 | 2006-06-13 | Research Foundation Of The State University Of New York | Groups of barrelia burgdorferi and borrelia afzelii that cause lyme disease in humans |
EP1235588A2 (en) * | 1999-12-09 | 2002-09-04 | Institut Pasteur | Systemic immune response induced by mucosal administration of lipid-tailed polypeptides without adjuvant |
US20030232055A1 (en) * | 2000-07-31 | 2003-12-18 | Ruslan Medzhitov | Innate immune system-directed vaccines |
CA2418036A1 (en) * | 2000-07-31 | 2002-02-07 | Yale University | Innate immune system-directed vaccines |
EP1939294A1 (en) | 2000-08-18 | 2008-07-02 | Research Foundation Of State University Of New York | Recombinant constructs of borrelia burgdorferi |
ES2298249T3 (es) | 2000-08-18 | 2008-05-16 | Research Foundation Of State University Of New York | Ospa modificada de borrelia burgdorferi. |
US20030175287A1 (en) * | 2001-01-03 | 2003-09-18 | Yale University | Innate immune system-directed vaccines |
EP1411770A4 (en) | 2001-07-05 | 2006-05-10 | Chiron Corp | POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE |
US7923023B2 (en) * | 2002-02-25 | 2011-04-12 | Astech International LLC | Method and composition for delivery of medicants to animals |
US20080299140A1 (en) * | 2002-05-24 | 2008-12-04 | The Regents Of The University Of California, | Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition |
FR2846004B1 (fr) * | 2002-10-16 | 2006-06-23 | Maco Pharma Sa | Composition pour culture de cellules notamment animales ou de tissus, comprenant du polyethylene glycol |
WO2005115430A1 (en) * | 2004-05-27 | 2005-12-08 | Gropep Limited | Treatment of inflammatory airway disease |
CA2576280A1 (en) | 2004-08-13 | 2006-02-16 | Barry J. Marshall | Helicobacter pylori-based delivery system |
US8029777B2 (en) | 2004-08-13 | 2011-10-04 | Marshall Barry J | Helicobacter system and uses thereof |
CA2638760A1 (en) | 2006-03-07 | 2007-09-13 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
US8466259B2 (en) * | 2007-12-07 | 2013-06-18 | National Health Research Institutes | Adjuvants |
TWI376385B (en) * | 2007-12-07 | 2012-11-11 | Nat Health Research Institutes | Production of lipidated proteins in e. coli |
EP2274616A1 (en) | 2008-04-22 | 2011-01-19 | The Research Foundation of State University of New York | Borrelia burgdorferi cell envelope protein array |
US8287880B2 (en) | 2009-06-02 | 2012-10-16 | National Health Research Institutes | Lipidated vaccine against dengue virus infection |
TWI409275B (zh) * | 2009-06-22 | 2013-09-21 | Nat Health Research Institutes | 脂質化腫瘤相關抗原及其免疫治療的組成物及方法 |
US20120237536A1 (en) * | 2009-09-10 | 2012-09-20 | Novartis | Combination vaccines against respiratory tract diseases |
TWI507413B (zh) | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | 脂質化多抗原表位疫苗 |
TW201221642A (en) | 2010-11-15 | 2012-06-01 | Nat Health Research Institutes | Method of producing lipidated polypeptides |
ES2615230T3 (es) | 2010-12-29 | 2017-06-06 | Oceanspar, Inc | Corral para peces con pértiga central y método para retener un pez en aguas abiertas |
AU2014359292B2 (en) | 2013-12-03 | 2019-02-28 | Swiss Tropical And Public Health Institute | Proline-rich peptides protective against S. pneumoniae |
JP2017531657A (ja) | 2014-10-07 | 2017-10-26 | ザ リサーチ ファンデーション フォー ザ ステート ユニバーシティ オブ ニューヨーク | 組換えボレリアタンパク質およびその使用のための方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK590288D0 (da) * | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
US4302386A (en) * | 1978-08-25 | 1981-11-24 | The Ohio State University | Antigenic modification of polypeptides |
EP0014815A3 (de) | 1978-12-20 | 1980-10-29 | Ciba-Geigy Ag | Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen |
US4258029A (en) | 1979-04-23 | 1981-03-24 | Connaught Laboratories Limited | Synthetic adjuvants for stimulation of antigenic responses |
US4455142A (en) | 1980-07-07 | 1984-06-19 | Alza Corporation | Method of coadministering an antigen and an immunopotentiator |
US4484923A (en) * | 1982-03-25 | 1984-11-27 | Alza Corporation | Method for administering immunopotentiator |
DE3521994A1 (de) | 1985-06-20 | 1987-01-02 | Bayer Ag | N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
US4839293A (en) * | 1986-02-24 | 1989-06-13 | The Trustees Of Columbia University In The City Of New York | DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof |
US4721617A (en) | 1986-08-14 | 1988-01-26 | Regents Of The University Of Minnesota | Vaccine against lyme disease |
EP0270295A3 (en) * | 1986-12-03 | 1989-08-02 | Connaught Laboratories Limited | Conjugate vaccine |
US4879213A (en) * | 1986-12-05 | 1989-11-07 | Scripps Clinic And Research Foundation | Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse |
US5098997A (en) * | 1987-12-11 | 1992-03-24 | Praxis Biologics, Inc. | Vaccines for Haemophilus influenzae |
WO1990003441A1 (en) | 1988-09-20 | 1990-04-05 | Marvin Murray | Accelerated microdilution determination of bacteria susceptibility to antibiotics |
ATE140461T1 (de) | 1989-12-22 | 1996-08-15 | Mikrogen Molekularbiol Entw | Immunologisch aktive proteine von borrelia burgdorferi, zusammenhängende testkits und impfstoff |
CA2032914A1 (en) * | 1989-12-26 | 1991-06-27 | Peter C.K. Lau | Use of bacterial lipoprotein amino terminus in fusion plasmids for in vivo expression of lipid modified polypeptides |
ATE168132T1 (de) | 1991-02-15 | 1998-07-15 | Uab Research Foundation | Strukturgen von pneumokokken-protein |
EP0877085A1 (en) * | 1991-08-15 | 1998-11-11 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | OspA protein of borrelia burgdorferi subgroups, encoding genes and vaccines |
AU681572B2 (en) * | 1991-10-21 | 1997-09-04 | Med Immune, Inc. | Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins |
AU2903892A (en) * | 1991-10-22 | 1993-05-21 | Symbicom Aktiebolag | Improvement in (borrelia burgdorferi) diagnosis and prophylaxis |
CA2105629A1 (en) * | 1992-09-14 | 1994-03-15 | Robert S. Becker | Potentiation of immunogenic response |
AU5958594A (en) * | 1992-12-24 | 1994-07-19 | Med Immune, Inc. | Method of protection against (streptococcus pneumoniae) with transformed mycobacteria |
FR2708622B1 (fr) * | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
-
1995
- 1995-06-07 US US08/476,656 patent/US6251405B1/en not_active Expired - Fee Related
-
1996
- 1996-01-19 US US08/588,621 patent/US6379675B1/en not_active Expired - Fee Related
- 1996-06-05 AT AT96919085T patent/ATE249844T1/de not_active IP Right Cessation
- 1996-06-05 IL IL118579A patent/IL118579A/en not_active IP Right Cessation
- 1996-06-05 EP EP96919085A patent/EP0831937B1/en not_active Expired - Lifetime
- 1996-06-05 JP JP9501336A patent/JPH11510370A/ja not_active Ceased
- 1996-06-05 WO PCT/US1996/008866 patent/WO1996040290A1/en active IP Right Grant
- 1996-06-05 AU AU61519/96A patent/AU717890B2/en not_active Ceased
- 1996-06-05 CA CA002223041A patent/CA2223041A1/en not_active Abandoned
- 1996-06-05 DE DE69630033T patent/DE69630033T2/de not_active Expired - Fee Related
- 1996-06-07 ZA ZA9604894A patent/ZA964894B/xx unknown
-
1997
- 1997-12-04 NO NO975620A patent/NO975620L/no unknown
- 1997-12-05 FI FI974423A patent/FI118591B/fi active IP Right Grant
-
2002
- 2002-03-12 US US10/096,687 patent/US6984385B2/en not_active Expired - Fee Related
-
2005
- 2005-07-01 US US11/173,364 patent/US7235243B2/en not_active Expired - Fee Related
-
2007
- 2007-05-18 US US11/804,446 patent/US20080089911A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ZA964894B (en) | 1997-02-24 |
IL118579A (en) | 2007-12-03 |
US6251405B1 (en) | 2001-06-26 |
IL118579A0 (en) | 1996-10-16 |
US6379675B1 (en) | 2002-04-30 |
US7235243B2 (en) | 2007-06-26 |
US20060110408A1 (en) | 2006-05-25 |
US6984385B2 (en) | 2006-01-10 |
DE69630033D1 (de) | 2003-10-23 |
FI974423A (fi) | 1998-02-04 |
AU717890B2 (en) | 2000-04-06 |
FI974423A0 (fi) | 1997-12-05 |
US20080089911A1 (en) | 2008-04-17 |
FI118591B (fi) | 2008-01-15 |
ATE249844T1 (de) | 2003-10-15 |
JPH11510370A (ja) | 1999-09-14 |
NO975620D0 (no) | 1997-12-04 |
EP0831937A4 (en) | 2001-09-19 |
AU6151996A (en) | 1996-12-30 |
EP0831937A1 (en) | 1998-04-01 |
CA2223041A1 (en) | 1996-12-19 |
EP0831937B1 (en) | 2003-09-17 |
US20020131983A1 (en) | 2002-09-19 |
WO1996040290A1 (en) | 1996-12-19 |
DE69630033T2 (de) | 2004-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO975620D0 (no) | Immunologiske kombinasjonssammensetninger og fremgangsmåter | |
NL300897I1 (nl) | Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit | |
UA49814C2 (uk) | Композиція, яка містить антиген вірусу папіломи, спосіб лікування цервікального раку, спосіб лікування гострокінцевої кондиломи | |
IS4518A (is) | Nýtt lyfjaform fyrir bóluefni | |
FI972945A (fi) | Antigeenien antamiseen soveltuvia koostumuksia | |
ATE284710T1 (de) | Adjuvans für vitale impfstoffe | |
DE3852761D1 (de) | Saponin-hilfsmittel. | |
DK0745388T4 (da) | Mammalt vaccinepræparat omfattende squalen eller squalan, phospholipid og et overfladeaktivt stof som adjuvans | |
DK0724432T3 (da) | Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner | |
BR9107206A (pt) | Processo para produzir uma variante de proteina que evoca uma resposta imunogenica diminuida em animais,produtos obtidos,composicao e uso | |
ES2143716T3 (es) | Composicion de vacuna que contiene adyuvantes. | |
RU98100200A (ru) | Антигены helicobacter pylori и вакцинные композиции | |
PT789590E (pt) | Imunopotenciacao induzida por quitosano | |
BR0111834A (pt) | Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno | |
ATE377428T1 (de) | Rotavirus-impfstoff | |
HK1085646A1 (en) | Antigenic compositions for immunization of non-human mammals against streptococcus equi | |
PT792165E (pt) | Composicoes imunogenicas | |
AU2001284354A1 (en) | Immunological adjuvant compounds, compositions, and methods of use thereof | |
SE9604296D0 (sv) | New pharmaceutical formulation of polypeptides | |
DK0757556T3 (da) | Borrelia Burgdorferi-bakterin | |
SE9604322D0 (sv) | Bacterial antigens and vaccine compositions II | |
ATE353226T1 (de) | Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form | |
ATE195427T1 (de) | Pertussistoxin enthaltender influenzaimpfstoff | |
AU4537100A (en) | Adjuvant combinations for immunization composition and vaccines | |
WO2002085409A3 (en) | Methods and compositions for inducing an immune response to an antigen |